Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hengren (HNGE) filing a Rule 144 notice reports proposed and recent sales of Common stock tied to restricted stock units and executed 10b5-1 plans. The filing lists 300,001 Restricted Stock Units with an 05/21/2025 grant date and multiple 10b5-1 sales in 2026 totaling 250, - (see detailed sale rows).
The notice itemizes three completed 10b5-1 trades: 33,333 shares on 04/21/2026, 50,000 shares on 04/01/2026, and 166,666 shares on 03/06/2026, with proceeds shown per trade.
Hinge Health, Inc. reported strong first quarter 2026 results with revenue of $182.3 million, up 47% from $123.8 million a year earlier, and GAAP gross margin improving to 85% from 81%.
GAAP income from operations rose to $32.1 million from $13.1 million, while GAAP diluted net income per share was $0.41 and non-GAAP diluted EPS was $0.45. Net cash provided by operating activities increased sharply to $43.1 million, driving free cash flow of $41.6 million. As of March 31, 2026, the company held $407.1 million in cash, cash equivalents, marketable securities and restricted cash.
Management raised full-year 2026 revenue guidance to a range of $798 million to $804 million, implying 36% year-over-year growth at the midpoint, and now expects non-GAAP operating margin of 26%. Hinge Health also highlighted 52% growth in last-12-months calculated billings to $769.9 million and a 23% increase in clients to 2,849.
Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 831 shares of Class A Common Stock were relinquished and cancelled at an indicated price of $44.60 per share to cover federal and state tax withholding obligations.
The footnote explains this exempt transaction under Section 16b-3(e) was a payment of tax liability by delivering or withholding securities, not an open-market sale. Following the withholding and cancellation, Pursley directly holds 730,442 shares of Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a routine share disposition tied to tax withholding obligations. On May 1, 2026, 4,614 shares of Class A Common Stock were relinquished and cancelled at an indicated value of $44.60 per share to cover federal and state taxes from vesting restricted stock units.
The footnote explains this exempt transaction was processed under Section 16b-3(e), with the issuer agreeing to satisfy the tax liability in exchange for the cancelled shares. Following this tax-withholding disposition, Budge held 392,199 shares of Hinge Health stock directly. This event reflects compensation-related tax settlement rather than an open-market sale.
Hinge Health, Inc. ownership filing: HANSAINVEST Hanseatische Investment-Limited Co reports beneficial ownership of 1,476,600 ordinary shares, representing 2.65% of Hinge Health's class of ordinary shares. The ownership figure is stated as of December 31, 2025 and the Schedule 13G was signed on April 27, 2026.
The filing states HANSAINVEST has sole voting and dispositive power over the shares under German law (Sec. 93 (1) KAGB) and notes the shares are held for the account of investment funds managed by HANSAINVEST.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported an insider transaction involving a conversion and sale of shares. He converted 33,333 shares of Class B Common Stock into Class A Common Stock and then sold 33,333 Class A shares in an open-market transaction at a weighted average price of $45.0463 per share, with prices ranging from $45.00 to $45.44, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, he reported direct ownership of 1,759,769 shares of Class B Common Stock and indirect Class B holdings convertible into 383,592 Class A shares through a family trust and 1,092,119 Class A shares through a GRAT, plus an additional 944,250 performance stock units that are excluded from the reported amounts.
Hinge Health, Inc. is holding its 2026 annual stockholder meeting virtually on June 3, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 10, 2026 can vote on electing two Class I directors, Teddie Wardi and Tyler Sloat, to terms ending at the 2029 meeting and on ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights that a majority of directors and all board committees are independent, and describes extensive risk oversight, cybersecurity, and executive compensation programs. The proxy also details significant 2025 equity-based pay for senior executives and the structure of director retainers and RSU grants.
Hinge Health, Inc. director Tyler Sloat acquired 68 shares of Class A Common Stock through the settlement of fully vested restricted stock units on April 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program. Following this equity grant, Sloat directly holds 9,964 Class A shares.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg converted 50,000 shares of Class B Common Stock into 50,000 shares of Class A Common Stock and then sold all of those Class A shares in open-market transactions.
The sales covered 49,332 shares at a weighted average of $38.448 and 668 shares at a weighted average of $39.0167, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. Following these trades, he held no Class A shares directly but continued to hold 1,793,102 Class B shares directly, plus additional Class B shares through a GRAT and a family trust that are convertible into over 1.47 million Class A shares. The filing also notes 944,250 performance stock units held by Mecklenburg, which are excluded from the share totals.